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Abstract
Background: The aim was to assess the feasibility of conducting a randomised controlled trial (RCT) of induction of
labour comparing use of two methods in the outpatient setting.
Methods: An open-label feasibility RCT was conducted in two UK maternity units from October 2017 to March
2019. Women aged ≥ 16 years, undergoing induction of labour (IOL) at term, with intact membranes and deemed
suitable for outpatient IOL according to local guidelines were considered eligible. They were randomised to cervical
ripening balloon catheter (CRB) or vaginal dinoprostone (Propess). The participants completed a questionnaire and
a sub-group underwent detailed interview. Service use and cost data were collected via the Adult Service Use
Schedule (AD-SUS). Women who declined to participate were requested to complete a decliners’ questionnaire.
Results: During the study period, 274 eligible women were identified. Two hundred thirty (83.9%) were
approached for participation of whom 84/230 (36.5%) agreed and 146 did not. Of these, 38 were randomised to
Propess (n = 20) and CRB (n = 18). Decliner data were collected for 93 women. The reasons for declining were
declining IOL (n = 22), preference for inpatient IOL (n = 22) and preference for a specific method, Propess (n = 19).
The intended sample size of 120 was not reached due to restrictive criteria for suitability for outpatient IOL,
participant preference for Propess and shortage of research staff.
The intervention as randomised was received by 29/38 (76%) women. Spontaneous vaginal delivery was observed
in 9/20 (45%) women in the dinoprostone group and 11/18 (61%) women in the CRB group. Severe maternal
adverse events were recorded in one woman in each group. All babies were born with good condition and all
except one (37/38, 97.4%) remained with the mother after delivery. No deaths were recorded. − 21% of women in
the dinoprostone group were re-admitted prior to diagnosis of active labour compared to 12% in the CRB group.
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Conclusions: A third of the approached eligible women agreed for randomisation. An RCT is not feasible in the
current service context. Modifications to the eligibility criteria for outpatient IOL, better information provision and
round the clock availability of research staff would be needed to reach sufficient numbers.
Trial registration: NCT03199820. Registered on June 27, 2017
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Key messages
 The study is not feasible using existing eligibility
criteria for outpatient induction of labour (IOL);
further modifications to the eligibility criteria for
outpatient IOL would be needed to make it feasible.
 Other reasons for the low recruitment rate were
participant preference for prostaglandin pessary and
shortage of research staff.
 No major adverse effects were recorded attributible
to the outpatient setting for induction of labour in
this small sample.
Introduction
Over the last decade, the rate of induction of labour
(IOL) in England has increased steadily to around 30%
of all pregnant women [1]. Currently, most women
undergoing induction of labour are admitted to the hos-
pital prior to commencing IOL. A Cochrane review
assessing methods of outpatient labour induction (cer-
vical ripening or priming) concluded that it was feasible
for labour to start at home. However, there is limited
evidence as to which induction methods are preferred by
women or the interventions that are most effective and
safe to use in outpatient settings [2]. A Cochrane review
reported that mechanical methods (trans-cervical balloon
catheter) of cervical ripening for IOL are as effective as va-
ginal prostaglandin PGE2 [3]. The UK Database of Uncer-
tainties about the Effects of Treatments (UK DUETs)
identified mechanical methods of labour induction as a
known uncertainty and recommended that future studies
on mechanical methods for IOL should have larger sam-
ple sizes and report on substantive outcomes. In a rando-
mised controlled trial [4], 101 women with an
unfavourable cervix requiring IOL at term were rando-
mised to outpatient care using Foley catheter or inpatient
care using vaginal PGE2. The authors reported that the
outpatient group had shorter hospital stay prior to birth
whilst vaginal birth rates, total induction to delivery time
and total inpatient times were similar. Another trial
showed that, for women with an unfavourable cervix at
term, success of induction of labour with a mechanical
method is similar to induction of labour with progstaglan-
dins, with fewer maternal and neonatal side effects, but
similar caesarean section rates [5]. Furthermore, Pennell
et al. [6] reported lower pain scores with the use of mech-
anical method as compared to prostaglandins. Both stud-
ies were apparently undertaken in an inpatient setting.
The OPRA study [7] compared clinical outcomes from
outpatient with inpatient prostaglandin treatment for low
risk labour induction. They concluded that uterine stimu-
lation following prostaglandins may preclude a woman
from going home or remaining at home overnight and
may not be the best agent for outpatient ripening. There-
fore, it would be beneficial to compare outpatient out-
comes of prostaglandin treatment with mechanical
methods including economic analysis to determine the
most suitable agent. The prostaglandin method is the
standard practice for IOL at St. George’s Hospital,
London, and Medway Hospital, Kent. Although mechan-
ical methods are used in some UK hospitals, outpatient
use is not common. The Hospital Episode Statistics (HES)
database does not record the exact method of induction of
labour nor collect data on efficacy, cost-effectiveness, hos-
pital stay or outcome of labour induction stratified accord-
ing to the method of induction of labour. Therefore, there
is no readily available data source that can be used to ob-
tain information on the outcomes of induction of labour
using mechanical methods in the outpatient setting. A re-
cent Cochrane review [3] concluded that future research
could be focused more on safety aspects for the neonate
and maternal satisfaction.
A feasibility trial was deemed necessary before
embarking on a randomised controlled trial. It would
permit identification of suitable clinical outcome mea-
sures with sufficient precision and help design a future
randomised controlled trial. The primary objective,
therefore, was to investigate the feasibility of conducting
a randomised controlled trial of induction of labour
using trans-cervical ballon catheter versus vaginal pros-
taglandin E2 pessary in the outpatient setting.
Methods
Study design
We conducted an open-label feasibility RCT (Registra-
tion Number: NCT03199820) with sustained-release
prostaglandin vaginal pessary (Propess) or cervical ripen-
ing balloon catheter (CRB) in the outpatient setting
using a 1:1 allocation ratio. The trial took place in two
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UK maternity units: St George’s University Hospitals
NHS Foundation Trust, South London (October 2017 to
March 2019) and Medway University Hospital, Kent
(February 2018 to October 2018). The two sites differed
in social demographics and were included to enhance
the external validity of the results. The study description
is publicly available at the clinical trials registry [8]. The
trial was approved by the East of England - Cambridge-
shire and Hertfordshire Research Ethics Committee (17/
EE/0295). The primary objective was to assess the feasi-
bility of conducting a randomised controlled trial (RCT),
namely, the number of women willing to enrol. Second-
ary objectives were to identify suitable clinical outcome
measures, estimate service costs and monitor safety, as
well as to determine women’s willingness to be rando-
mised, to determine the acceptability of using the bal-
loon catheter, to examine women’s views on outpatient
induction of labour and to assess women’s experience
with these methods and their preference. Assessment of
women’s experience with these methods and their pref-
erence was through interviews and qualitative analysis
and will be reported elsewhere.
Participants
Inclusion criteria were women aged ≥ 16 years, undergoing
IOL at ≥ 37weeks’ gestation, with intact membranes, able
to give informed consent and deemed suitable for out-
patient IOL according to local guidelines. Written informa-
tion was provided to women regarding the available
methods: IOL with sustained release dinoprostone (Pro-
pess), or cervical ripening balloon (CRB), both in the out-
patient setting. Research teams at each site approached
women to confirm eligibility and provided verbal and writ-
ten information. Strict eligibility criteria have been devel-
oped for suitability of outpatient IOL against which
research midwives screened for eligible participants and a
medical practitioner confirmed that eligibility was met. At
both the recruiting sites, the pregnancy had to be uncom-
plicated at or beyond 41+0 weeks with a single foetus in
cephalic presentation with no risk factors. Trained clinician
obtained written informed consent. During the study, the
investigators noticed a shortfall of eligible women. There-
fore, inclusion criteria were widened in 2018 at St. George’s
Hospital to include women requiring induction of labour at
term (37+0 weeks or more) with diet-controlled gestational
diabetes, who were originally excluded.
Randomisation and masking
Eligible participants were randomly allocated with a 1:1
ratio to receive Propess or CRB. Randomisation was
stratified by site and parity using variable block sizes
(two and four). A research team member entered base-
line data on a web-based database at study enrolment
and then allocated the treatment (Propess or CRB) using
the web-based randomisation programme developed by
the King’s Clinical trial Unit (KCTU). Nature of the
intervention mandated that trial participants, clinical
care providers or outcome assessors could not be
blinded to trial allocation. The statistician was not aware
of the allocation sequence and discussions as regards re-
cruitment and was not involved in any of the women’s
care or recording of their results. The data were supplied
to the statistician by the Clinical Trials Unit with the
group allocation coded. The group allocation was only
revealed following compilation of the results in tabular
form.
Procedures
After randomisation, a member of the research team ad-
ministered the treatment method according to the rec-
ommendations of the manufacturer, described briefly as
follows: for induction of labour with Propess, 10mg insert
was introduced in the posterior vaginal fornix close to the
cervix, using only small amounts of water-soluble lubri-
cants to aid insertion. The woman was advised to be re-
cumbent for 20-30min following insertion. For IOL with
balloon catheter, the woman was positioned in the dorsal
position and a vaginal speculum was inserted to gain cer-
vical access. The cervix was cleaned appropriately to pre-
pare for device insertion. The CRB was inserted into the
cervix and advanced until both balloons entered the cer-
vical canal. The uterine balloon was inflated with 40ml
sodium chloride (0.9%). Once the uterine balloon was in-
flated, the device was pulled back until the balloon was
against the internal cervical os. The vaginal balloon was
now inflated with 20ml NaCl (0.9%). The speculum was
removed after the balloons were situated on each side of
the cervix and the device was securely in place. More fluid
was added to each balloon in turn, in 20ml increments
until each balloon contained 80ml (maximum volume of
fluid). Following this, clinical care was provided by clinical
healthcare practitioners.
Women underwent monitoring of foetal condition and
uterine activity by cardiotocography (CTG) according to
the local protocol. CTG was discontinued once it was
judged to be normal and the woman could go home.
She was instructed to return to the hospital at an agreed
time on the following morning, if the balloon catheter
was spontaneously expelled or if she thought she was in
labour, whichever was earlier. On the following morn-
ing/upon onset of labour, the device (Propess or CRB)
was removed, and artificial rupture of membranes
(ARM) attempted (unless spontaneous rupture had oc-
curred already).
The intended recruitment target was randomisation of
120 women between the two sites over a 12-month
period. Ability to recruit the intended sample size was
considered the demonstration of feasibility.
Bhide et al. Pilot and Feasibility Studies           (2020) 6:113 Page 3 of 9
Sample size
The study was designed as a feasibility trial, and as sug-
gested by NIHR guidelines [9], no formal sample size
calculation was performed. It has been recommended
that the total sample size for a feasibility trial can be be-
tween 70 (with allocation to treatments groups in a 1:1
ratio, i.e. 35 per group) if the outcome for the definitive
RCT is normally distributed and a total of at least 120
subjects (60 per group) for binary outcomes [10]. It was
important to allow for incomplete data and protocol vio-
lation. Therefore, it was thought more efficient to use
the larger sample size to guard against the lack of preci-
sion by using inflated estimates. Therefore, the intended
sample size would provide information on the primary
outcome measures with sufficient accuracy to inform a
power calculation for the definitive randomised con-
trolled trial.
Women who declined to participate in the trial were
invited to complete a short questionnaire exploring their
main reasons for not participating. Verbal feedback was
obtained for those who declined to complete the ques-
tionnaire. After they had given birth, the participants
were asked to complete a questionnaire within 48 h. The
questionnaire was modified from the one used in a pre-
viously published study [4]. This recorded women’s ex-
perience and acceptability of the two methods. All
women who took part in the RCT were also invited to
participate in a semi-structured interview at least 4
weeks after the birth. Partners were also invited with the
women’s permission. The detailed methods and findings
of the interviews as well as the post-natal questionnaire
will be reported in a separate paper.
Participant demographics and clinical and patient-
reported data were collected using an online database
developed by KCTU. The clinical and patient-reported
data included vital signs at trial entry, cervical Bishop
score, birth details, maternal and foetal outcomes includ-
ing adverse outcomes, use of pain relef measures at
home and in the hospital, survey responses and decliner
questionnaire responses.
The Adult Service Use Schedule (AD-SUS) was used
to collect service use data [11]. It is a researcher-
completed questionnaire, adapted for use in this study
following a review of relevant and in collaboration with
the clinical research team. The AD-SUS was completed
using data from electroinc hospital records. Since this
was a feasibility study, the usefulness of the instrument
was judged by the ease of completion by the research
staff and its ability to provide the data needed to gener-
ate costs for a full economic evaluation. The method for
estimating the cost of the alternative interventions for
this study required work in a feasibility stage because of
the need to capture all aspects of induction. Service use
data were reviewed in order to establish the most
accurate approach to estimating the cost and alternative
methods were compared. The options for sources of unit
costs for the intervention and associated resources were
also explored, making use of nationally available costs
and optimising links with the service use data.
Research teams undertook standard assessments of
safety, with reporting of adverse events and serious ad-
verse events following usual governance procedures for a
clinical trial of an investigational medicinal product
overseen by the UK Medicines and Healthcare Regula-
tory Agency (MHRA).
Statistical analysis
The analysis and presentation of results follow the
CONSORT guidelines [12] (Fig. 1). All analyses followed
the intention-to-treat principle: all randomly allocated
women (and infants) were analysed according to the
group they were allocated to, irrespective of the inter-
vention they received. Demographic and clinical data
were presented as frequencies and percentages for cat-
egorical variables and mean and standard deviation for
normally distributed continuous variables. Statistical hy-
pothesis testing was not performed since this was a
feasibility study.
Role of funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation or writing of
the report. The corresponding author had full access to
all the data in the study and had final responsibility for
the decision to submit for publication.
Results
Feasibility outcomes
Between October 16, 2017, and March 31, 2019 (18
months), 3293 women (2167 at St George’s and 1126 at
Medway) underwent IOL. Out of these, 274 women
(8.32%) were found to be eligible for inclusion according
to local criteria for outpatient IOL. Of the 274 eligible
women, 230 (83.9%) were approached for participation
of whom 84 (36.5%) agreed (two/month/site). Of these,
46 women were excluded for reasons including ARM
and delivery by IOL date. The remaining 38 women
were randomised: Propess (n = 20), CRB (n = 18). Of
the 146 women not agreeing to participate, 93 com-
pleted a questionnaire. Reasons for declining participa-
tion (please see Table 1) included declining IOL (n =
22), preference for inpatient IOL (n = 22) or for a spe-
cific method (Propess, n = 19). Of those randomised
women, nine (24%) did not receive the intervention they
were originally allocated (details in the Consort Flow-
chart). Feasibility outcomes according to the participat-
ing centre are shown in Table 2.
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Clinical characteristics
Participant demographics at randomisation are shown in
Table 3. The women had a mean height of 168.9 cm,
mean weight 69.1 kg and mean BMI 24.2 kg/m2, whilst
25/38 (65.8%) were nulliparous. The majority of women
29/38 (76%) were of white European ethnicity. The mean
age of women in the Propess group was 34.1 years, com-
pared to 33.2 years in the CRB group.
Maternal and foetal parameters at baseline are shown
in Table 4. Maternal vital signs were within the
Fig. 1 CONSORT diagram of the trial
Table 1 Decliners’ information
No. of women
Total women declining participation 117
Decliners’ data available 93
Verbal response 70
Decliners’ questionnaire 23
Main reason for declining
Preferring inpatient IOL 22/93
Declining IOL by any method 22/93
Preferring Propess 19/93
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reference range at baseline, post-treatment and at
follow-up. No uterine activity was detected at baseline in
either of the two groups. The median Bishop score at
study entry for both groups was unfavourable (Propess,
4; CRB, 3, Table 4). The clinical outcomes are shown in
Table 5. The device (vaginal pessary or balloon catheter)
was expelled in four (10.5%) of women. Seven of the 38
participants could not go home after intervention (Table
5). Epidural use for labour analgesia was reported by 20/
38 (52.6%) of women. Nearly two thirds (61%) of the
women in the cervical balloon group had a spontaneous
vaginal delivery, compared to 45% in the dinoprostone
group. Delivery was by caesarean section in 14 (36.8%)
women. The rates of caesarean section were 33% (6/18)
in the CRB group and 40% (8/20) the Propess group.
Median gestational age at delivery was 41+6 weeks.
Mean birthweights were similar between groups (Propess,
3688.7 gm; CRB, 3684.2 gm). All babies except one (37,
97.4%) remained with the mother after delivery. No ma-
ternal or foetal deaths were recorded in this small sample.
The health economic outcomes are as follows: the
AD-SUS service use questionnaire was easy to complete
from patient records and the completeness of the data
was excellent; 95% of participants had full service use
data available at follow-up. Close monitoring over the
data collection period ensured that we are confident that
all relevant resources were included in the analysis. Full
data at follow-up were available for 36 of the 38 rando-
mised women. The costs of induction and readmission
prior to delivery were estimated to be similar between
the two randomised groups. Total costs were £2880.82
in the CRB group and £3389.63 in the Propess group
(please see Table 5). This difference was accounted for
by differences in mode of birth and it cannot be as-
sumed from this small sample that a difference in mode
of birth would be found with bigger numbers.
Table 2 Feasibility outcomes by centre and for all participants
SGH Medway All participants
Women delivering in the study period (n) 2167 1126 3292
Number of eligible participants (n, %) 168 (7.75%) 106 (9.41%) 274 (8.32%)
Number of participants approached (n, %) 156 (92.9%) 74 (69.8%) 230 (83.9%)
Participants randomised (n, %) 30 (19%) 8 (10%) 38 (16.5%)
Received allocated intervention (n, %) 23/30 (76.7%) 6/8 (75.0%) 29/38 (76.3%)
Did not receive allocated intervention (n, %) 7/30 (23.3%) 2/8 (25.0%) 8/38 (21.1%)
Withdrew from trial intervention (n) 0 1 1
Complete data available (n, %) 23 (76.6%) 5 (62.5%) 28 (73.7%)
Post-natal patient questionnaire completed (n, %) 23 (76.6%) 5 (62.5%) 28 (73.7%)
Declined post-natal patient questionnaire (n) 0 1 1
Agreed for post-natal interview (n) 14 7 21
Underwent post-natal interview (n) 14 7 21
SGH St. George’s University Hospital, London, Medway Medway University Hospital, Kent
Table 3 Demographics of randomised participants
Participant characteristics Propess (n = 20) CRB (n = 18)
Site
SGH
Medway
16
4
14
4
Mean age (SD) in years 34.1 (4.48) 33.2 (4.32)
Mean height (SD) in cm 166.62 (6.25) 171.59 (7.1)
Mean weight (SD) in kg 71.84 (11.9) 65.96 (11.0)
Mean BMI (SD) in kg/m2 25.72 (2.9) 22.37 (3.3)
Ethnicity
White 15 (75%) 14 (78%)
Black 1 (5%) 2 (11%)
Asian 1 (5%) 0
Mixed 1 (5%) 2 (11%)
Other 1 (5%) 0
Not known 1 (5%) 0
Mean gestational week (SD) at delivery 41.71 (0.61) 41.63 (0.53)
Marital status
Married 15 (75%) 7 (39%)
Cohabiting 4 (20%) 8 (44%)
Single 1 (5%) 0
Not recorded 0 3 (17%)
Employment
Employed 16 (80%) 18 (100%)
Unemployed 2 (10%) 0
Not recorded 2 (10%) 0
Nulliparous 13 (65%) 12 (67%)
Parous 7 (35%) 6 (33%)
Data reported as mean (SD) or n (%)
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Women’s willingness to be randomised
Data were collected on reasons for declining participa-
tion. Overall, 93 women supplied decliners’ data with 23
women completing a decliner’s questionnaire and 70
women providing verbal responses. The most common
reasons for declining to take part were as follows: prefer-
ring to have inpatient IOL (n = 22; 24%), declining IOL
by any method before 42 weeks (n = 22; 24%) and pre-
ferring to have PGE2 pessary (n = 19; 20%).
Discussion
The number of women eligible for outpatient induction
was much lower than anticipated. Reasons for under-
recruitment included understaffing and not having the mid-
wife(s) available to screen women every day and women’s
preference to a method, in particular prostaglandin pessary.
Suitability of outpatient induction is dependent on the local
criteria. Units with restrictive criteria will have a limited
number of women deemed suitable for outpatient induc-
tion of labour. A widening of inclusion criteria may increase
numbers of potential participants. The study is not feasible
using existing criteria and further modifications to the eligi-
bility criteria for outpatient IOL would be needed to make
an RCT feasible. At Medway Hospital, consenting women
underwent an artificial rupture of membranes (ARM) if
feasible rather than entry into the trial due to a policy
change. This led to a reduction in the pool of possible par-
ticipants limiting recruitment. Therefore, further recruit-
ment at Medway Hospital was stopped. Choice of another
suitable unit where consenting women were allowed to par-
ticipate in the study could have helped with recruitment.
Approximately a third of all eligible women in this study
(84/230, 36.5%) were prepared to participate in a trial
where the method of induction of labour in the outpatient
setting (dinoprostone or CRB) is chosen at random. Par-
ticipant numbers were limited further by clinical factors,
particularly women going into labour spontaneously be-
fore the CR method was inserted, and a smaller number
of women withdrawing after recruitment. A previous
study by Henry et al. [4] exploring outpatient Foley cath-
eter versus inpatient prostaglandin E2 gel for induction of
labour reported that out of the 262 women found eligible
for inclusion, 101 (38.5%) agreed and were randomised.
This rate is very similar to that observed in this study, al-
though the Henry study took place in Australia.
Outpatient induction of labour is not common in the
UK. In a survey of outpatient IOL [13], a postal ques-
tionnaire was sent to 210 NHS consultant-led obstetric
units within the UK, of which 78% responded. Only
17.6% of units reported that they currently or soon will
provide outpatient IOL. The rate of use may have in-
creased since this survey but routine data are not avail-
able. Outpatient IOL may benefit the working of
midwives as well. A survey exploring the impact of out-
patient IOL on midwives’ work found that their job sat-
isfaction either increased or was unchanged in an
overwhelming majority (93%) of respondents [14].
More than one half of those women approached in this
study declined to participate. The most common reasons for
declining to take part were preferring to have inpatient IOL,
declining IOL by any method before 42weeks, plus preferring
to have PGE2 pessary. Since a trial of this nature cannot be
blinded, there is also a possibility that agreement to continue
in a trial may be skewed by women’s prior attitudes. This is
reflected in the reasons given for declining, and CRB was not
standard practice in these services; preference for this method
could equally have been a motivator for participation. Mech-
anical methods have been reported as being safer than prosa-
glandins for labour induction [15]. However, that study was
published relatively recently and the findings not widely dis-
seminated. Improved information provision may remove this
obstacle and provide eligible women with a wider choice.
A majority of women who were randomised received
the intended intervention and were able to go home. De-
livery was by caesarean section in 14 (36.8%) women. All
babies were born with good condition and only one baby
did not stay with the mother after delivery. Severe com-
plications were reported only in a small minority (Table
5). One woman from the CRB group experienced severe
post-partum haemorrhage (2.1 L) and one woman from
the Propess group underwent a category 1 caesarean
section for antepartum haemorrhage.
Table 4 Maternal and foetal clinical parameters at baseline
Parameter Propess (n = 20) CRB (n = 18)
Mean pulse (SD) in BPM 83.4 (10.35) 80.8 (9.63)
Mean systolic BP (SD) in mmHg 118.7 (9.71) 117.2 (12.40)
Mean diastolic BP (SD) in mmHg 76.9 (5.52) 77.3 (8.08)
Mean temperature (SD) in Celsius 36.7 (0.20) 36.6 (0.24)
Mean respiratory rate in breaths/min (SD) 16.4 (1.26) 16.1 (1.19)
Mean foetal heart rate (SD) in BPM 137.6 (12.18) 141.3 (12.83)
Median number (IQR) of contractions/10 min 0 (0 to 0) 0 (0 to 0)
Median Bishop score (IQR) 4 (3.0 to 4.0) 3.0 (2.8 to 4.3)
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Table 5 Clinical and health economic outcomes
Participant outcome Propess (n = 20) CRB (n = 18)
Intervention expelled
No 15 (75%) 14 (78%)
Yes 3 (15%) 1 (6%)
Missing 2 (10%) 3 (16%)
Return for admission
Agreed time next morning 5 (25%) 4 (22%)
Labour 10 (50%) 5 (28%)
Participant never went home following intervention 3 (15%) 4 (22%)
Missing 2 (10%) 5 (28%)
Epidural use
No 8 (40%) 9 (50%)
Yes 12 (60%) 8 (44%)
Missing 0 1 (6%)
Live birth 20 (100%) 18 (100%)
Mode of birth
SVD 9 (45%) 11 (61%)
Caesarean section in labour 6 (30%) 2 (11%)
No labour caesarean section 2 (10%) 4 (22%)
Instrumental delivery 3 (15%) 1 (6%)
Median estimated blood loss in ml (IQR) 320.0 (200.0 to 675.0) 600.0 (225.0 to 1145.0)
Mean birthweight in gm (SD) 3688.7 (310.00) 3684.2 (293.33)
Boy 14 (70%) 6 (33%)
Girl 6 (30%) 11 (61%)
Not recorded 0 1 (6%)
5 min Apgar score median (IQR) 10.0 (10.0 to 10.0) 10.0 (10.0 to 10.0)
Head circumference in cm (mean, SD) 35.2 (1.54) 35.1 (1.36)
Where did the baby go?
To mother 20 (100%) 16 (89%)
NICU admission 0 1 (6%)
Missing 0 1 (6%)
Any adverse event experienced
Mother alone 8 (40%) 6 (33%)
Baby alone 1 (5%) 3 (17%)
Both mother and baby 4 (20%) 2 (11%)
None 7 (35%) 7 (39%)
Severe adverse event
None 18 (90%) 17 (94%)
Mother alone 1† (10%) 1 (6%)
Baby alone 0 0
Both mother and baby 0 0
Maternal death 0 0
Foetal/neonatal death 0 0
Health economic outcomes Propess (n = 19) CRB (n = 17)
Cost of induction and readmission prior to delivery, mean (SD) 135.47 (206.56) 127.29 (198.33)
Bhide et al. Pilot and Feasibility Studies           (2020) 6:113 Page 8 of 9
Not all women who desired to go home could go home.
Twenty-nine percent of the participating women could re-
main home overnight in this study. Wilkinson et al. [7] re-
ported that less than half the women participating in an
RCT comparing inpatient versus outpatient cervical ripen-
ing could remain at home overnight. However, all women
had received vaginal prostaglandin E2 gel [7].
Conclusions
The study is not feasible using existing eligibility criteria for
outpatient induction of labour (IOL). Further modifications
to the eligibility criteria for outpatient IOL improved
provision of information on safety and better availability of re-
search staff may be helpful to make such a trial feasible. The
trial procedures were acceptable to women who participated.
Although the sample size of this feasibility trial was limited,
no major adverse effects attributible either to the setting or
the method for induction of labour were recorded. Service
use data can be collected in a vast majority of participants.
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Table 5 Clinical and health economic outcomes (Continued)
Participant outcome Propess (n = 20) CRB (n = 18)
Cost of delivery, mean (SD) 3254.16 (965.10) 2753.53 (712.31)
Total cost, mean (SD) 3389.63 (1023.94) 2880.82 (717.04)
†One mother experienced two severe adverse events (haemorrhage and infection)
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